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INTRODUCTION 
 
Most of the solid tumors have a steadily growing incidence 
and, in the majority of cases, not primary tumor growth but 
distant metastases are the main cause of death. Metastasis 
formation is a complex process that requires a spatiotemporal 
regulation of cell adhesion, cell proliferation and cell 
migration. Thus, investigation of these cellular processes and 
the connection between cell migration and cell proliferation is 
extensively studied. 
Based on experimental data and on the concept that 
cytoskeletal machinery cannot be used for proliferation and 
migration concurrently, the “go or grow” hypothesis - 
formulated for tumor cells - postulates that migration and cell 
division are mutually exclusive, and tumor cells defer 
proliferation for cell migration. Most experimental and 
theoretical approaches addressing the “go or grow” hypothesis 
have been performed on intracranial tumor cells of 
neuroectodermal origin and the data is rather conflicting. In 
the context of glioma the regulation of FAK expression, the 
mir451/ LKB1/AMPK or mir9/CREB/NF1 signaling and 
carboxypeptidase E (CPE) expression were proposed as 
molecular mechanisms that could lead to migration and 
proliferation dichotomy, respectively. 
The “go or grow” hypothesis is particularly important in the 
development of effective anti-cancer drugs that can also target 
the survival-prone subpopulation of tumor cells being able to 
escape from the primary tumor and survive in metastatic tissue 
microenvironment. If tumor cells defer cell proliferation for 
cell migration than migrating cells should have a decreased 
sensitivity to treatment modalities targeting the proliferating 
tumor cells. Thus, anti-proliferative therapies may 
unintentionally select for migratory cells or even induce cell 
migration in surviving cell populations. Furthermore, 
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inhibition of cell migration might induce the proliferation of 
disseminating cells and lead to primary or secondary tumor 
growth. For this reason, understanding better the connection 
between proliferation and migration is essential for the 
development of therapies inhibiting both of these cellular 
processes. Since evaluation of the “go or grow” hypothesis is 
currently largely based on brain tumor cells, in this thesis, we 
extended the investigation of this hypothesis on 2D cell 
cultures of tumor cell lines originating from different 
embryonic cell layers such as cells of neuroectodermal, 
mesodermal and entodermal origin, using long-term time-lapse 
videomicroscopy. 
The currently available anticancer treatment modalities often 
interact with members of the various growth factor (GF) and 
TGF signaling pathways to influence proliferation and 
migration. EGF acting on EGFR and FGF2 activating all four 
types of FGFRs have extensively overlapping downstream 
signaling cascades, as Ras and Raf play a central role in the 
downstream activation of both EGF and FGF2 signaling. 
Impaired EGF and FGF2 signaling is involved in a great 
variety of malignancies and pro-tumorigenic effect of the 
signaling of both ligands is proven in malignant melanoma. 
Furthermore EGF and FGF2 signal transduction is affected by 
oncogenic driver mutations in BRAF or NRAS, which are 
present in about 40 to 70% and in 10 to 30% of melanoma 
cases, respectively. Inhibition of EGF/FGF2 signaling can be 
exerted on the level receptors (monoclonal antibodies and 
receptor tyrosine kinase inhibitors) and on the level of the 
downstream elements. A currently investigated mechanism for 
the latter is the treatment with zoledronic acid that inhibits 
prenylation, which is a post-translational modification step of 
Ras. The facts that both EGF and FGF2 act on extensive 
overlapping downstream signaling networks and that the most 
common oncogenic mutations in malignant melanoma are 
activating mutations of their downstream effectors led us to 
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investigate the activation and inhibition of EGF and FGF2 
signaling on melanoma cells with different NRAS and BRAF 
mutational status. 
Activin is a member of TGFβ signaling family. It is a dimeric 
protein and interacts with several activin type I and type II 
receptors. In tumors, activin signaling can be associated with 
both inhibition and promotion of cell proliferation and tumor 
progression. In hepatocellular carcinoma, breast cancer and 
prostate cancer, activin signaling takes part in inhibition of cell 
proliferation and tumor progression. In contrast, activin can 
promote cell proliferation in endometrial carcinoma, oral 
squamous cell carcinoma, testicular and gastric cancer and in a 
great variety of thoracic tumors like esophageal squamous cell 
carcinoma, esophageal adenocarcinoma and lung 
adenocarcinoma. One of the exogenous antagonists against the 
activin type I is SB-431542 that acts on all three activin type I 
receptors. Since activin has been shown to be pro-tumorigenic 
in a variety of thoracic tumors and malignant mesothelioma 
lacks for targeted therapy our aim was to investigate the 
potential effect of inhibiting activin signaling in human 
mesothelioma cells. 
Altogether, growth factor receptor signaling and oncogenic 
mutations affecting this pathway are major regulators of the 
spatiotemporal interplay and activation of cell migration and 
proliferation in human tumor cells. In the PhD dissertation we 
investigated the following research question. 
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OBJECTIVES 
 
1. Do human tumor cells defer proliferation to cell migration 
in adherent cultures as it had been postulated in the “go 
or grow” hypothesis? Accordingly, we measured 
proliferation, migration and length of cytokinesis in 35 
lung cancer, melanoma and mesothelioma cell lines by 
videomicroscopy and performed correlation analysis 
between these cellular processes at both single cell and 
population level. 
2. Does invasion of the ECM from multicellular spheroids 
require concurrent cell proliferation? We raised this 
question because a number of mathematical models of 
3D matrix invasion of tumor cells incorporate the 
assumption that proliferation is a prerequisite to invasive 
behavior, however, there was no experimental evidence 
available for this. In order to evaluate this hypothesis we 
characterized the invasion pattern of proliferating and 
proliferation-inhibited cells from multicellular spheroids 
into collagen type I gel.  
3. Do BRAF and NRAS oncogenic mutations determine the 
migratory and proliferative response of melanoma cells 
to activation and inhibition of EGFR and FGFR? First, 
BRAF and NRAS oncogenic mutations as well as EGFR 
and FGFR expression of melanoma cells were 
determined. Then, migration and proliferation as well as 
the activation of downstream signaling were explored 
under baseline conditions and after treatment with EGF 
and/or FGF or with the inhibitors of these receptors. 
4. Does prenylation inhibition interfere with migration, 
proliferation and the activity of Ras signaling pathway 
in human melanoma cells in vitro and in vivo? BRAF 
and NRAS mutation dependent effect of ZA treatment 
on cell migration, proliferation and apoptosis induction 
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was determined in melanoma cells in vitro. Furthermore, 
the effect of ZA on primary tumor growth and 
metastasis formation was assessed using animal models 
of melanoma cells with different mutational status.  
5. Does activin signaling support or interfere with migration 
and proliferation of human mesothelioma cells? 
Accordingly, we assessed the effect of activin and 
activin-receptor inhibitor SB431542 treatment on cell 
proliferation, cytokinesis and migration in human 
mesothelioma cells via videomicroscopy. 
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METHODS 
 
Cell lines 
Thirteen melanoma, twelve mesothelioma, ten lung cancer and 
two brain tumor derived human cell lines were used in the 
studies. 
 
Compounds/drugs 
The following compounds were used in the experiments: EGF, 
FGF2, the FGFR inhibitors ponatinib, BGJ-398, BIBF-1120, 
AZD-4547, the EGFR inhibitors gefitinib, erlotinib, CI-1033, 
pelitinib, the prenylation inhibiting zoledronic acid (ZA), 
activin and the activin inhibitor SB-431542. 
 
Videomicroscopy 
Duration of cytokinesis, cell proliferation and migration was 
assessed in adherent 2D cell cultures by the evaluation of long 
term phase-contrast microscopy time-lapse recordings. 
 
Collagen invasion assay 
Glioma cell pellets were drawn into pipette tips and 
cylindrical aggregates were embedded into collagen gel 
and photographed to evaluate 3D migration pattern. 
 
Mutation analysis  
Genomic DNA was isolated from pellets of melanoma 
cells and oncogenic mutations in BRAF and NRAS were 
investigated via microcapillary restriction fragment length 
analysis and by direct DNA sequencing. 
 
Quantitative PCR 
Total RNA was isolated and reverse transcription was 
performed. Next, quantitative real-time PCR was used to 
measure expression of EGFR and FGFRs in melanoma cells. 
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Cell viability assay 
Adherent cells cultures were fixed using trichloroacetic acid 
after treatment and total protein amount was measured 
colorimetrically after SRB staining to evaluate cell viability. 
 
Apoptosis assay 
Apoptosis induced by zoledronic acid treatment was assessed 
using TUNEL staining on PFA fixed cell cultures and direct 
counting of the TUNEL-positive cells. 
 
Activation of cell signaling 
Actiavtion of Erk1/2, S6, FAK and Src proteins was quantified 
by immunoblot analysis phosphorylation of these proteins in 
human melanoma cells. 
 
In vivo subcutaneous xenograft model 
To examine the effect of ZA on primary tumor growth, 
human melanoma cells were injected subcutaneously into 
the flank region of NSG mice, treated intraperitoneally 
on a weekly basis and tumor volumes were evaluated. 
 
In vivo spleen to liver colonization assay 
In order to investigate the effect of ZA on metastatic 
potential, colonization experiment from spleen to liver 
was performed in NSG mice. Animals were treated 
intraperitoneally for three weeks before the spleen and 
liver were removed and weighed.  
 
Statistical analysis 
All statistical analyses were computed in GraphPad Prism 5. 
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RESULTS 
 
Migration/proliferation dichotomy in 2D cell cultures 
Since migration, proliferation and the interplay of these 
cellular processes, postulated by the “go or grow” hypothesis, 
are crucial in terms of tumor progression and investigated 
currently in central nervous system tumors we evaluated this 
hypothesis on tumor cell lines with neuroectodermal, 
mesodermal and entodermal origin. Videomicroscopy 
recording and assessment of migration, proliferation and 
cytokinesis-length were performed on both individual cells 
and on population levels in 2D cell cultures of thirty-five (12 
mesothelioma, 13 melanoma and 10 lung) cancer cell lines. 
Significantly higher averaged 24-hour migration distance was 
found in mesothelioma cells when compared to melanoma and 
lung cancer cells. Average expected number of cell divisions 
within 24hs showed a range of one order of magnitude and the 
highest averaged proliferation was found in mesothelioma 
cells followed by proliferation of melanoma and lung cancer 
cells. The average duration of one division showed no 
significant differences between the three tumor subtypes. 
The statistical correlations between the probability of cell 
division, the average migrated distance and the duration of 
cytokinesis has been established in all three tumor types. 
Interestingly, a strong positive correlation was found between 
cell proliferation and cell migration in melanoma cells and in 
lung cancer cells, as well; whereas, no correlation was 
observed in the examined mesothelioma cell lines  
Correlation between average duration of cytokinesis and cell 
migration was calculated for each tumor type. Interestingly, 
significant negative correlation was found between duration of 
cytokinesis and cell migration in melanoma cell lines. There 
was no significant correlation between cytokinesis and 
migration in mesothelioma and lung cancer cells. Correlation 
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between cell proliferation and duration of cytokinesis was 
significant in mesothelioma cells but failed to show 
significance in melanoma and lung cancer cells. 
Since the FAK/Src signaling is an important regulatory 
pathway in 2D migration, activation of FAK and Src kinases 
were explored by examining total and phosphorylated amount 
of proteins via immunoblot assay. Next, we divided melanoma 
cell lines into two groups at the median migratory potential 
and averaged the activation for the six slowest and six fastest 
migrating melanoma cells. Interestingly, activation of FAK 
tended to be higher in fast migrating melanoma cells. In 
contrast, activation of Src was essentially equal in fast and 
slow migrating cells. 
 
Proliferation and migration in 3D cell cultures 
Interplay between proliferation and migration plays an 
important role in 3D tumor growth and invasion. Since 
proliferation is thought to be a prerequisite for the 3D 
extracellular matrix invasion of tumor cells, the 
interdependence of proliferation and migration was studied in 
glioblastoma cells. Our evaluation was also included in a 
novel mathematical model that describes the invasion patterns 
of tumor cells into the surrounding matrix. Accordingly, cell 
invasion from an aggregate into a surrounding ECM was 
studied in the presence/absence of a cell proliferation inhibitor. 
Nevertheless, the invasion patterns and migrated distances in 
the first 24 hours after treatment were essentially the same in 
division inhibited and control cells. 
 
Oncogenic mutations in melanoma cells 
In order to evaluate whether the most important oncogenic 
mutations indeed influence migration and cell division in a 
distinct manner in melanoma, mutational status of the 
investigated cell lines were determined. Altogether four cell 
lines with BRAF (V600E), two cell lines with NRAS (Q61K 
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and Q61R) mutations and two cell lines wild-type for these 
genes were used for the experiments. 
 
Ligand dependent activation of EGFR and FGFR in 
melanoma 
Prior to testing the activation of EGFR and FGFR receptors on 
melanoma cells with known mutational status, expression of 
EGFR and FGFR relative to GAPDH was investigated by 
qPCR. High expression of EGFR, FGFR1 and FGFR4 was 
confirmed in each of the investigated cell lines. Interestingly, 
FGFR2 and FGFR3 were not expressed in the two NRAS-
mutant cell lines. In general, the lowest expression of growth 
factor receptors was found in the double wild-type cells. 
Ligand activation of EGFR and FGFR was investigated by 
treating cells with 50 ng/ml EGF, FGF2 or both during 
videomicroscopy rmeasuerments. Proliferation and migration 
of untreated cells with different oncogenic mutations was 
compared first. Importantly, both BRAF and NRAS activating 
mutations resulted in elevated levels of migration and 
proliferation compared to double wild type cells. The 
difference inthe average migrated distance of BRAF-mutant 
and double wild type cells was statistically significant. 
Mutational status dependent effect of EGF and/or FGF2 
treatment on proliferation and cell viability of melanoma cells 
was tested both via videomicroscopy and SRB-assay. There 
was only a modest increase of cell proliferation in double 
wild-type cells, but not in cells with BRAF or NRAS 
oncogenic mutations upon treatment. 
Videomicroscopy recordings were also used to define the 
mutation-dependent effect of EGF and/or FGF2 treatment on 
migration. The migratory effect was more profound compared 
to the effect seen in proliferation and convincing effect on 
migration was only seen in double wild type cells. Migration 
in both double wild type cell lines increased upon treatment 
with GFs but EGF caused more elevated migratory activity 
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than FGF2 in both cell lines. Importantly, the combined 
treatment resulted in a further increase in migration when 
compared to treatment with EGF or FGF2 alone. Although 
significantly elevated migration was observed in the NRAS-
mutant cell line M24met after FGF2 treatment, this increase 
was considerably smaller than those observed in double wild 
type cells. When taking the average migration distance in cell 
lines having the same mutation status, BRAF-mutant cells 
failed to show altered migration after treatment with GFs and 
NRAS-mutant cells showed only a modest increase in 
migration in response to FGF2 or combined growth factor 
treatment. 
Phosphorylation of two major downstream effectors, Erk1/2 
and S6, were explored using immunoblot measurement to 
assess the activation of growth factor receptor pathway. Under 
baseline conditions, BRAF and NRAS oncogenic mutations 
resulted in a higher phosphorylation of Erk1/2 and S6 as 
compared to wild type cells. 
Treatment with GFs elevated the level of phosphorylation of 
Erk1/2 and S6 in double wild type cells in a much higher 
proportion as compared to either BRAF or NRAS mutant 
cells. Generally, the alteration of Erk1/2 and S6 
phosphorylation measured in cells harboring oncogenic 
mutations was rather modest when compared to the double 
wild type response. 
 
Inhibition of EGFR and FGFR in melanoma 
Since activation of the EGF/FGF signal transduction was 
found to be dependent on the oncogenic mutation in melanoma 
cells, the pharmacological inhibition of EGFR and FGFR was 
also compared in the melanoma cells with different oncogenic 
mutations. 
The oncogenic mutation dependent inhibition of EGF and FGF 
signaling was performed by treating the cells for 72 h with 
EGFR (gefitinib, erlotinib CI-1033 and pelitinib) and FGFR 
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(ponatinib, BGJ-389, BIBF-1120 and AZD-4745) inhibitors 
and viability was measured via SRB assay. Independent of 
their mutational status, cell lines were largely insensitive to 
gefitinib and erlotinib treatment. Although CI-1033 and 
pelitinib treatment were somewhat effective, there was no 
difference between the sensitivity of cells having different 
mutations. Similarly, the effect of FGFR inhibition on cell 
viability was also independent of cells being BRAF- or 
NRAS-mutant or wild type for these genes. 
 
Oncogenic mutation-dependent prenylation inhibition 
response in melanoma 
Posttranslational modification – including prenylation among 
others – of Ras is one of the major regulators of its activity and 
oncogenic RAS mutations play a major role in malignant 
melanoma. Thus, the effect of prenylation inhibition was 
examined by zoledronic acid (ZA) treated human melanoma 
cell lines carrying either mutant BRAF or NRAS or none of 
them. After the 24-hour-treatment, the BRAF-mutant cells 
displayed a profound change in morphology. These cells 
obtained a rather elongated form, whereas only modest or no 
change was found in NRAS-mutant or in double wild-type 
cells.  
Effect of the treatment with different concentrations of ZA on 
cell viability of melanoma cells was measured by SRB-assay. 
ZA treatment clearly decreased cell viability in NRAS mutant 
cells even in smaller doses. Cell viability of BRAF mutant and 
double wild type cells were decreased only to a smaller extent 
and at higher doses. 
Videomicroscopy measurements were used to evaluate the 
effect of ZA treatment on migration of melanoma cells. 
Despite the significant increase in the migration of one of the 
NRAS-mutant cell lines and one of the double wild type cells, 
ZA treatment increased the migratory activity of BRAF-
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mutant cells to a much higher extent compared to NRAS 
mutant and double wild type cells. 
In order to characterize the pro-apoptotic effect of ZA, 
TUNEL staining was performed on melanoma cell lines 
treated with 25μM ZA. Though both NRAS-mutant cell lines 
were sensitive to ZA treatment, there was a huge difference in 
their sensitivity level. In average, there was a more profound 
pro-apoptotic effect of ZA treatment in NRAS-mutant cells 
compared to BRAF mutant and double wild type cells. Of 
note, amount of apoptotic cells found in the TUNEL assay was 
in line with the measured reduction in cell viability. 
Since a robust apoptotic effect in NRAS mutant melanoma 
was found the activation of the ribosomal protein S6 a 
downstream target of RAS involved in the regulation of 
survival was investigated via immunoblot assay. Interestingly, 
the treatment with ZA resulted in the increased activation of 
ribosomal protein S6 in M24met NRAS mutant cells and in a 
decreased activation in the other NRAS mutant cell line. This 
differential reduction of S6 activation was in accordance with 
the results seen in the TUNEL assay. 
To examine the effect of ZA on primary tumor growth, human 
melanoma cells were injected subcutaneously into the flank 
region of NSG (NOD scid gamma) mice. ZA treatment failed 
to show an inhibitory effect on subcutaneous tumor growth of 
injected melanoma cells. In order to investigate the metastasis 
related effects of ZA, colonization experiment of spleen to 
liver was performed. As a result, ZA failed to inhibit the 
metastatic growth of NRAS-mutant or double wild-type 
melanoma cells and it exerted only modest inhibition on 
metastatic growth of BRAF-mutant melanoma cells. 
Importantly, the lower dose (50μg/kg) of ZA resulted in a 
significantly higher metastasis formation in double wild-type 
cells. 
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Modulation of the activin signaling in mesothelioma 
 
Activin signaling can be associated with both inhibition and 
promotion of tumor progression in various types of tumors. 
However, the role of this signaling pathway in mesothelioma 
has not been investigated yet. Videomicroscopy measurements 
were performed to investigate the effect of activin A (20 
ng/ml), the inhibitor SB431542 (20 μM) or the combination of 
these two agents on cell proliferation and cell migration. 
Treatment with the activin receptor inhibitor SB-431542 alone 
or in combination decreased the proliferation of M38K 
mesothelioma cells significantly compared to control. In 
contrast, there were no differences in the proliferation of P31 
cells upon inhibition or activation of the activin receptors. 
Unlike cell proliferation, migration of M38K cells was 
increased after activin treatment, whereas migration of P31 
cells remained unaffected. 
Videomicroscopy provides a unique opportunity to identify 
aberrant cytokinesis, which was observed in P31 
mesothelioma cell line even under control conditions. Almost 
2 percent of mitoses were multipolar even in untreated cell 
populations. Interestingly, treatment with activin receptor 
inhibitor SB-431542 alone or combined with activin resulted 
in a significantly higher proportion of multipolar (in majority 
tripolar) cytokineses as compared to control. 
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CONCLUSIONS 
 
1. Revisiting the “go or grow” hypothesis, no negative 
correlation between proliferation and migration and thus 
no supporting evidence for the hypothesis was found. In 
contrast, positive correlation was found between 
migration and proliferation in melanoma and lung 
cancer cells. 
2. Our experiments using collagen embedded multicellular 
brain tumor cell spheroids demonstrated that the 
invasion process in 3D matrices did not require 
concurrent cell proliferation.  
3. Investigation of the mutational status dependence of EGF 
and FGF response revealed a lower baseline activity and 
higher inducibility of proliferation and migration in 
double wild-type melanoma cells compared to cells with 
oncogenic BRAF or NRAS mutation. In contrast, 
response to GF receptor tyrosine kinase inhibitors was 
oncogenic mutation independent. 
4. Investigation of the mutation dependence of prenylation 
inhibition resulted in a decrease of proliferation in 
NRAS mutant melanoma cells but in the increase of 
migration in vitro and increased metastatic potential in 
vivo in BRAF mutant and double wild type melanoma 
cells, respectively. The apoptosis induction in NRAS 
mutant melanoma suggests that prenylation targeting 
treatment modalities may be effective in this molecular 
subgroup of melanoma. 
5. In certain mesothelioma cells, migratory and proliferative 
response to the induction and inhibition of activin 
signaling conferred a pro-tumorigenic effect of activin 
activation. The presented results suggest that activin 
may be a valuable candidate for therapeutic interference. 
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